Patients Denied Access to PCSK9 Inhibitors Have Worse Cardiovascular Outcomes

Adverse cardiovascular outcomes were more prevalent among patients with rejected or abandoned PCSK9 inhibitor prescriptions, new research suggests.

The researchers looked specifically at the hypothesis that outcomes such as acute coronary syndromes, coronary interventions, stroke, and cardiac arrest would be more prevalent among patients without the PCSK9 inhibitor coverage. The study, published in Circulation: Cardiovascular Quality and Outcomes, identified 139,036 individuals who were prescribed a PCSK9 inhibitor between August 2015 and December 2017, who had claims history, and who had established dates of exposure for paid, rejected, or abandoned status. The team used propensity score matching to minimize confounding due to baseline characteristics in both patient groups. The authors defined “paid” as having paid PCSK9 inhibitor coverage for 168 or more days during a 12-month period.

According to the results, the hazard ratios were 1.10 (95% CI, 1.01 to 1.19; P=0.02) in the “rejected” group (compared to paid) and 1.12 (95% CI, 1.01 to 1.24; P=0.03) in the “abandoned” group (compared to paid). A stricter analysis (defining “paid” as 338 or more days of therapy in a 12-month period showed hazard ratios of 1.16 (95% CI, 1.02 to 1.30; P=0.04) for rejected versus paid, and 1.21 (95% CI, 1.04 to 1.38; P=0.03) for abandoned versus paid.

“Individuals in the rejected and abandoned cohorts had significantly increased risk of cardiovascular events compared with those in the paid cohort,” the authors wrote. “Rejection, abandonment, and disparities related to PCSK9 inhibitor prescriptions are related to higher cardiovascular outcome rates.”

Due to their high cost, access to PCSK9 inhibitors can be uneven, and disparities were more likely to affect minority populations, those in lower income groups, and women.

“We demonstrate[d] that individuals with primary prevention familial hypercholesterolemia and secondary prevention atherosclerotic cardiovascular disease statistically have no difference in risk of future cardiovascular events, and both high-risk cohorts were denied access to PCSK9 inhibitors is at the same rate as the general population.”

 

 

Eric Raible is editor of the Cardiology section of DocWire News and has more than a decade’s worth of experience in covering and publishing in the cardiology space. Eric has previously served as a founding editor of CardioSource WorldNews, and is a former staff writer and editor of Cardiology Today.